Stabilised prostaglandin composition

• US 8,709,482 B2
• Filed: 05/31/2013
• Issued: 04/29/2014
• Est. Priority Date: 08/05/2004
• Status: Expired due to Fees

• Current Assignee: Ferring BV (Ferring Holding SA)
• Original Assignee: Ferring BV (Ferring Holding SA)
• Inventors: Robertson, Steven
• Primary Examiner(s): DICKINSON, PAUL W
• Application Number:
  US13/906,905
• Publication Number:
  US 20130261179A1
• Time in Patent Office: 333 Days
• Field of Search: None
• US Class Current: 424/486
• CPC Class Codes: A61K 31/557 Eicosanoids, e.g. leukotrienes or prostaglandins
• CPC Class Codes: A61K 31/5575 having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
• CPC Class Codes: A61K 47/30 Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
• CPC Class Codes: A61K 9/0031 Rectum, anus
• CPC Class Codes: A61K 9/0036 Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
• CPC Class Codes: A61K 9/006 Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
• CPC Class Codes: A61K 9/02 Suppositories; Bougies; Bases therefor; Ovulesapparatus for making A61J3/08; devices for introducing into the body A61M31/00
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/04 for inducing labour or abortion; Uterotonics
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A pharmaceutical delivery device, such as a suppository or pessary, comprises a synthetic prostaglandin PGE₁ analogue (e.g. misoprostol) in a solid polyurethane hydrogel.

Claims

1. A pharmaceutical delivery device, comprising:

a formulation comprising misoprostol in a polyurethane hydrogel, wherein the hydrogel has a water content of less than 0.2% by weight.

2. The delivery device of claim 1, wherein the polyurethane hydrogel is a cross-linked hydrogel.

3. The delivery device of claim 2, wherein the cross-linked hydrogel is the reaction product of a polyethylene glycol, a triol and a diisocyanate.

4. The delivery device of claim 3, wherein the polyethylene glycol has a molecular weight ranging between 4000 and 35,000.

5. The delivery device of claim 4, wherein the polyethylene glycol has a molecular weight ranging between 4000 and 8000.

6. The delivery device of claim 3, wherein the polyethylene glycol is selected from the group consisting of PEG2000, PEG4000, PEG6000 and PEG8000.

7. The delivery device of claim 3, wherein the triol is hexanetriol.

8. The delivery device of claim 3, wherein the diisocyanate is selected from the group consisting of dicyclohexylmethane diisocyanate, dicyclohexylmethane-4,4-diisocyanate, diphenylmethane-4,4-diisocyanate, and 1,6-hexamethylene diisocyanate.

9. The delivery device of claim 1, wherein the polyurethane hydrogel is a linear hydrogel.

10. The delivery device of claim 1, wherein the misoprostol is present in the formulation in an amount ranging between 25 and 400 μ

g.

11. The delivery device of claim 10, wherein the misoprostol is present in the formulation in an amount of 100 μ

g.

12. The delivery device of claim 10, wherein the misoprostol is present in the formulation in an amount of 200 μ

g.

13. The delivery device of claim 1, wherein the hydrogel has a water content of less than 0.1% by weight.

14. The delivery device of claim 1, wherein the hydrogel has a water content in the range of 0.1% to 0.2% by weight.

15. The delivery device of claim 1, further comprising butylated hydroxyl anisole.

16. The delivery device of claim 1, wherein the device is selected from the group consisting of a suppository, a vaginal pessary, a buccal insert and an implant.

17. A method for inducing labor, comprising:

contacting the delivery device of claim 1 with a body cavity.

18. The method of claim 17, wherein the delivery device is a vaginal pessary.

19. An article, comprising:

the pharmaceutical delivery device of claim 1, and

a desiccant.

20. The delivery device of claim 1, wherein the misoprostol is present in the formulation in an amount ranging between 100 and 400 μ

g.

21. The delivery device of claim 1, wherein the misoprostol is present in the formulation in an amount ranging between 100 and 200 μ

g.